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Abstract
Background: Medical textbooks often list Legionnaires’ disease as a differential diagnosis of the syndrome of
inappropriate secretion of anti-diuretic hormone (ADH) (SIADH), but evidence supporting this association is largely
lacking. We tested the hypothesis whether hyponatremia in patients with Legionnaires’ disease would be caused by
increased CT-ProVasopressin.
Methods: We measured CT-ProVasopressin and sodium levels in a prospective cohort of 873 pneumonia patients
from a previous multicentre study with 27 patients having positive antigen tests for Legionella pneumophila.
Results: Patients with Legionnaires’ disease more frequently had low sodium levels (Na < 130 mmol/L) (44.4% vs
8.2%, p < 0.01), but similar mean CT-ProVasopressin levels (pmol/l) (39.4 [±7] vs 51.2 [±2.7], p = 0.43) as compared to
patients with pneumonia of other etiologies. In patients with Legionnaires’ disease, CT-ProVasopressin levels showed
a positive correlation with sodium (r = 0.42, p < 0.05). Independent of pneumonia etiology, CT-ProVasopressin
correlated significantly with the pneumonia severity index (r = 0.56, p < 0.05), ICU admission (adjusted odds ratio per
decile, 95% CI) (1.6, 1.2 - 2.0), and 30-day-mortality (1.8, 1.3 - 2.4).
Conclusion: While Legionnaires’ disease was associated with hyponatremia, no concurrent increase in CT-ProVasopressin
levels was found, which argues against elevated ADH levels as the causal pathway to hyponatremia. Rather, Vasopressin
precursors were upregulated as response to stress in severe disease, which seems to overrule the osmoregulatory
regulation of ADH.
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Background
Low sodium levels are a common feature of patients
with community-acquired pneumonia (CAP), particu-
larly if caused by Legionella pneumophila [1-4]. In a
retrospective study comparing clinical features of CAP
caused by Legionella with CAP of other aetiology, low
sodium levels (<131 mmol/L) were present in 46% of pa-
tients with Legionnaires’ disease as compared to only
14% in patients with CAP of other aetiology [3]. Yet, the
physiopathological mechanisms underlying this sodium
imbalance remain unclear and evidence from controlled
studies is largely lacking. Previous smaller studies found
evidence for dysregulation of anti-diuretic hormone (ADH)
causing the syndrome of inappropriate secretion of ADH
(SIADH) in patients with tuberculosis. This was evi-
denced by detectable circulating levels of ADH despite
low sodium levels in patients [5,6]. More recent reports
linked inflammation to low blood sodium levels through
an immuno-neuroendocrine pathway with non-osmotic
release of vasopressin by interleukin (IL)-6 and other cyto-
kines (reviewed in [7]). Other studies again found that
changes in arterial PaCO2 and oxygenation stimulated hor-
mone release from the posterior and anterior pituitary
gland resulting in sodium disturbances [8]. Finally, a direct
renal involvement in patients with Legionnaires’ disease
causing renal salt wasting has been postulated [9].
Correctly diagnosing the underlying cause of low sodium
levels has important therapeutic consequences. Whereas
patients with sepsis clearly benefit from early fluid resus-
citation [10], free water restriction is recommended in
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patients with SIADH, because of the relative excess of
free water to solute caused by the antidiuretic hormone.
Finally, hyponatremia accounts for considerably increased
morbidity and mortality, mainly due to brain-function
alterations. Groups at increased risk are pre-menopausal
females, children, and patients with liver disease and
hypoxia [11-15].
Despite the lack of strong empirical evidence linking
low sodium levels to a specific pathophysiological path-
way, medical textbooks often list Legionnaires’ disease as
a differential diagnosis of SIADH. Diagnosing SIADH is
challenging in clinical practice, partly because of the analyt-
ical challenges of ADH measurement [16]. With the recent
availability of an immuno-assay that measures the more
stable ADH precursor peptide CT-ProVasopressin showing
a close correlation with ADH blood levels [17,18], we
sought to investigate whether elevated ADH precursor
levels would causatively explain the typical low blood so-
dium levels of patients with Legionnaires’ disease in a large
and well defined cohort of CAP patients from a previous
trial [19]. Particularly, we tested the hypothesis that pa-
tients with Legionella CAP and low sodium levels would
display increased levels of CT-ProVasopressin.
Methods
Setting and population studied
The present study used data from 873 patients from a co-
hort of 925 patients with radiologically confirmed CAP,
who had a sodium level measured on admission and
a left over blood sample for later measurement of CT-
ProVasopressin levels. A detailed description of the previ-
ous study has been published elsewhere [19,20] and was
published in the clinicaltrials.gov database (NCT00350987).
In brief, this was a multicenter, randomized-controlled
non-inferiority trial investigating the effects of using procal-
citonin for antibiotic stewardship compared to guideline
recommendations. Patients with lower respiratory tract
infections admitted to emergency departments of one of
six hospitals in Switzerland between December 2006 and
March 2008 were consecutively included. The primary end-
point was the combined medical failure rate of patients. A
study website provided information on the evidence-based
management of all patients based on the most recent
guidelines [21-24] and explicitly specified the need for
X-ray confirmation of CAP, collection of two sets of
pre-treatment blood cultures as well as urinary antigen
tests for diagnosis of Legionnaires’ disease.
The ethical committee of Basel (EKBB), Switzerland
approved the study and all patients gave written informed
consent.
Participants
Inclusion criteria for patients were written informed
consent, age ≥ 18 years and admission from the community
or a nursing home with the main diagnosis of CAP.
Exclusion criteria were the inability to provide written
informed consent, insufficient German language skills,
active intravenous drug use, previous hospitalisation
within 14 days, severe immunosuppression other than
corticosteroids, accompanying chronic infection or endo-
carditis and severe medical co-morbidity where death
was imminent. CAP was defined by the presence of at
least one respiratory symptom (cough, with and without
sputum production, dyspnea, tachypnea, pleuritic pain)
plus one auscultatory finding or one sign of infection
(core body temperature > 38.0°C, shivers, white blood
count > 10 G/L or < 4 G/L cells) and a new infiltrate on
chest radiograph [24,25].
Definitions
In all CAP patients, the protocol specified to perform
a qualitative immunochromatographic antigen test for
Legionella pneumophila serogroup 1 on urine samples
on admission (BinaxNow Legionella; Binax). In patients
with high suspicion for Legionnaires’ disease despite
negative urinary antigen, additional microbiological tests
(culture results from respiratory specimen or PCR from
respiratory specimen) were performed based on the dis-
cretion of the treating physician. Thus the gold standard
for diagnosis of Legionnaires’ disease in this study was
the clinical diagnosis of a CAP with an infiltrate on chest
X-ray and at least one positive microbiological test for
Legionella (urinary antigen testing, culture results from
respiratory specimen or PCR from respiratory specimen).
In addition, the protocol specified to collect two pairs of
blood cultures under both aerobic and anaerobic condi-
tions before starting antibiotic therapy. Blood cultures
were processed using an automated colorimetric detection
system (BacT/ALERT, bioMerieux, Durham, NC, USA)
in three hospitals and an equivalent blood culture sys-
tem (BACTEC Becton-Dickinson, Cockeysville, Md.)
in the other three hospitals [26]. If blood culture bot-
tles indicating bacterial growth, samples were Gram
stained and sub-cultured. The correct identification of
the pathogen was achieved according to routine laboratory
procedures.
Clinical examination and laboratory data
In all patients on admission, a thorough clinical examin-
ation was performed and two prognostic scores (Pneu-
monia Severity Index (PSI) and the CURB-65) were
calculated [27,28]. For all patients laboratory results
were collected from the routine blood analysis on admis-
sion including markers of infection (PCT, CRP and WBC)
and plasma sodium concentrations. CT-ProVasopressin
(pmol/L) was detected in stored EDTA plasma samples
of all patients with a new sandwich immunoassay (B.R.A.
H.M.S Sevapressin®LIA, B.R.A.H.M.S AG, Hennigsdorf/
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Berlin, Germany). Briefly, for the assay 50 μl of either
serum or plasma are required and no extraction steps or
other pre-analytical procedures are necessary. The analyt-
ical detection limit is 0.4 pmol/L and the functional assay
sensitivity (< 20% inter assay CV) was < 1 pmol/L. In 200
healthy individuals CT-ProVasopressin plasma concentra-
tion had a median of 3.7 pmol/L [29].
Statistical analysis
Discrete variables are expressed as counts (percentage)
and continuous variables as medians and interquartile
ranges (IQR) or means and standard deviations (SD).
Frequency comparison was done by chi-square test.
Two-group comparison Mann–Whitney-U test was
used. Receiver-operating-characteristics (ROC) were cal-
culated using STATA 9.2 (Stata Corp, College Station,
Tex). All testing was two-tailed and P values less




Of a total of 873 CAP patients, 31 (3.6%) had a final
diagnosis of Legionnaires’ disease. Of these, 4 patients
were excluded due missing CT-ProVasopressin levels
leaving 27 patients (3.1% of all CAP patients) for the
final analysis, All Legionella patients had a positive urine
antigen test. Legionella pneumophila was also cultured
from respiratory secretions in three cases. There were
no patients with Legionnaires’ disease which was de-
tected by other means than urinary antigen test. In the
overall CAP cohort, a total of 69 patients (7.9%) had
positive blood cultures, mainly with growth of Strepto-
coccus pneumoniae (86%), none with Legionella sp.
Patients with Legionnaires’ disease were similar in
terms of age and comorbidities compared to those with
CAP of other etiology (Table 1). The acuity of disease on
presentation at the emergency room tended to be higher
in Legionella patients for some clinical parameters such as
body temperature and markers of inflammation (C-reactive
protein). Also, clinical outcomes tended to be worse in
patients with Legionnaires’ disease with significantly higher
ICU admission rates and a trend for longer length of hos-
pital stays. Yet, no significant difference in severity of
illness scores (PSI, CURB65) was detected.
CT-ProVasopressin and sodium levels
Mean (SD) sodium levels were significantly lower in
patients with Legionnaires’ disease (131.6 mmol/l (±0.9) vs.
135.4 mmol/l (±0.2), p < 0.001) as compared to patients
with other CAP etiologies. A total of 44.4% of patients with
Legionnaires’ disease had sodium levels <130 mmol/l
as compared to only 8.2% of CAP patients with other eti-
ologies (p < 0.001). In contrast, mean CT-ProVasopressin
levels were not increased in patients with Legionnaires’
disease (39.4 pmol/l (±7) vs 51.2 pmol/l (±2.7), p = 0.43)
(Figure 1).
When comparing CT-ProVasopressin levels with so-
dium levels, we found no negative correlation in patients
with Legionnaires’ disease which would be expected when
ADH precursors were causatively related to hyponatremia.
In contrast, ADH precursors showed a positive correlation
with sodium levels (r = 0.42, p < 0.05) arguing against this
hypothesis (Figure 2). Similarly, in patients with other
CAP etiologies, there was a slight positive correlation of
CT-ProVasopressin and sodium levels without reaching
statistical significance (r = 0.06, p = 0.07).
To test the hypothesis that CT-ProVasopressin would
be causal in the relationship of Legionella etiology
and low sodium levels, we calculated multivariate re-
gression models with stepwise inclusion of one or
both parameters. There was again a strong associ-
ation of Legionella etiology and low sodium levels
(Table 2). This association was independent of age,
gender, severity as assessed with the CURB65 score
and markers of inflammation, infection and renal func-
tion. When also controlling for CT-ProVasopressin by
adding this parameter into the regression model, the
association of Legionella sp. etiology and low sodium
was virtually unchanged, again suggesting that CT-
ProVasopressin was not involved in the physiopatho-
logical pathway.
CT-ProVasopressin and severity of disease
In patients with Legionnaires’ disease, and also in all
other patients, sodium levels were not associated with
severity of pneumonia assessed with the CURB65 score
(p = 0.14 in Legionnaires’ disease, p = 0.3 in other CAP
Figure 3A). However, patients showed a stepwise in-
crease of CT-ProVasopressin with increasing CURB65
score (p < 0.01 for both populations Figure 3B). A similar
significant increase was found for PSI classes (r = 0.56,
p < 0.05). Thus, CT-ProVasopressin was mainly increased
in response to severity, and this was independent of blood
sodium levels.
To investigate the prognostic potential of CT-
ProVasopressin, we also investigated its association with
mortality and ICU admission. In a multivariate logistic re-
gression model including the CURB65 score, CT-
ProVasopressin was an independent predictor for death
(adjusted OR per decile increase in CT-ProVasopressin
(pmol/L): 1.8 (95% CI 1.3-2.4), AUC 0.73) and for ICU ad-
mission (adjusted OR per decile increase in CT-
ProVasopressin (pmol/L): 1.6 (95% CI 1.2-2.0), AUC 0.68).
Thereby, CT-ProVasopressin significantly improved the
CURB65 score for prediction of death (AUC improvement
from 0.72 to 0.77, p < 0.05) and for ICU admission (AUC
improvement from 0.64 to 0.69, p < 0.01).
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Discussion
Although textbooks commonly list Legionnaires’ disease
as a differential diagnosis in patients with SIADH, scien-
tific evidence linking low sodium levels commonly found
in Legionnaires’ disease to SIADH is sparse [30,31]. The
pathophysiologic differentiation is crucial, since SIADH
should be treated with free water restriction, whereas
sepsis requires volume replacement at the same time for
hemodynamic management. Within this large study of
consecutive patients with CAP of different etiologies and
severities, we tested the hypothesis that low sodium levels
in Legionnaires’ disease could be explained by inappropri-
ately high levels of CT-ProVasopressin. Importantly, our
results dismiss this hypothesis, since hyponatremic pa-
tients did not display high CT-ProVasopressin levels. In
contrast there was a positive correlation between sodium
and CT-ProVasopressin levels. This was also confirmed in
a multivariate model where Legionella sp. etiology of CAP
was a strong predictor for low sodium levels, independent
of disease severity, which remained unchanged after inclu-
sion of CT-ProVasopressin into the model again arguing
against a causal pathway.
Within this secondary analysis of a former prospective
study, we sought to explore the role of ADH in hypona-
tremia a finding more specific to Legionnaires’ disease
compared to CAP of other etiologies. ADH is not rou-
tinely measured in the work-up of SIADH, partially be-
cause of the analytical challenges of ADH measurement.
Instead, the diagnosis of SIADH is based on clinical fea-
tures and includes hyponatremia and hypoosmolality in
plasma while the patient is in an euvolemic state. Urine
osmolality and sodium are inappropriately high in the
absence of edema-forming states, thyroid and adrenal
dysfunction [32]. Yet, with the recent availability of an
Table 1 Baseline characteristics (n = 873)
Parameter All CAP patients Legionnaires’ disease Other CAP etiology p
n = 873 n = 27 n = 846
Demographics
Age (years), mean (SD) 68.3 (±0.6) 64.9 (±3.1) 68.4 (±0.6) 0.35
Male gender, n (%) 512 (58.7%) 20 (74.1%) 492 (58.2%) 0.09
Comorbidities, n (%)
Congestive heart failure 151 (17.3%) 2 (7.4%) 149 (17.6%) 0.16
COPD 266 (30.5%) 3 (11.1%) 263 (31.1%) 0.03
Diabetes 149 (17.1%) 6 (22.2%) 143 (16.9%) 0.47
Tumor 109 (12.5%) 2 (7.4%) 107 (12.7%) 0.42
Chronic renal failure 195 (22.3%) 7 (25.9%) 188 (22.2%) 0.65
Clinical presentation, mean (SD)
Heart rate (beats/min) 95.7 (±0.7) 101.3 (±3.9) 95.5 (±0.7) 0.12
Blood pressure systolic (mmHg) 133.1 (±0.8) 136.5 (±4.1) 133 (±0.8) 0.45
Respiratory rate (breaths/min) 22.1 (±0.3) 25.7 (±3.4) 22 (±0.3) 0.052
Temperature (°C) 38 (±0.1) 38.7 (±0.2) 38 (±0.1) 0.012
Blood analysis on admission, mean (SD)
Sodium (mmol/l) 135.3 (±0.2) 131.6 (±0.9) 135.4 (±0.2) <0.001
Sodium < 130 mmol/l, n (%) 81 (9.3%) 12 (44.4%) 69 (8.2%) <0.001
C-reactive protein (mg/l) 178.4 (±4.5) 334.2 (±23.6) 173.4 (±4.4) <0.001
Procalcitonin (μg/l) 4.4 (±0.5) 4.1 (±0.9) 4.4 (±0.5) 0.92
CT-ProVasopressin (pmol/l) 50.9 (±2.6) 39.4 (±7) 51.2 (±2.7) 0.43
Risk scores on admission, mean (SD)
PSI score 92 (±1.2) 101.4 (±6) 91.7 (±1.2) 0.17
CURB65 score 1.5 (±0) 1.4 (±0.2) 1.5 (±0) 0.61
Hospital outcomes
Mortality, n (%) 49 (5.6%) 2 (7.4%) 47 (5.6%) 0.68
ICU admission, n (%) 79 (9.1%) 9 (33.3%) 70 (8.3%) <0.001
Length of stay (days), mean (SD) 9.8 (±0.3) 12.3 (±1.8) 9.7 (±0.3) 0.09
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immuno-assay measuring the more stable ADH precursor-
peptide (CT-ProVasopressin) that is produced in equimolar
ratio to ADH, this problem can now be addressed [33].
Clinical studies have shown a very high correlation
of CT-ProVasopressin with ADH, demonstrating that
CT-ProVasopressin indeed can be used a surrogate for
ADH production in clinical practice [34-36]. Still, dif-
ferent distinct ADH patterns in patients with an estab-
lished diagnosis of SIADH may exist which further
challenge the interpretation of laboratory results [37]. First,
a reset osmostat with a positive correlation of ADH and
osmolality set for total ADH suppression lower than the
physiologic osmolality threshold of about 280 mOsm/kg.
This usually results in a constant and asymptomatic mild
hyponatremia. Second, a constant and non-suppressible
ADH secretion independent of plasma osmolality, caused
by a constant ectopic or neurohypophyseal release. Third,
hyponatremia with completely suppressed ADH secre-
tion while still maintaining an inappropriate amount of
antidiuresis and thus causing hyponatremia. In addition,
in some patients no good correlation may be found be-
tween ADH levels and plasma osmolality, although pa-
tients formally fulfill the diagnosis of SIADH. As our
study has focused on laboratory results only, these data
need confirmation in a trial where patients volume sta-
tus as well as urinary electrolytes are taken into ac-
count as well.
Few reports investigated ADH levels in CAP patients.
A study including 28 adult CAP patients reported in-
creased ADH levels and impairments in renal water
excretion [6,38]. Similarly, in children with tubercu-
losis and respiratory syncytial virus (RSV) pneumonia,
increased ADH levels were described and correlated
with the degree of hypoxia and hypercapnia [5,39-44].
While, we also documented increased levels of CT-
ProVasopressin in our study of CAP patients, there was
no association of high ADH precursor levels and low so-
dium levels. Yet, CT-ProVasopressin showed a stepwise
increase with increasing severity of disease. Thus, the
subtle increase in ADH precursor level in CAP patients
with hyponatremia is likely due to a stress response
which overrules the osmoregulatory function. This find-
ing is consistent with several observational studies dem-
onstrating that high blood levels of CT-ProVasopressin
are associated with adverse clinical course and mor-
tality in patients with sepsis and respiratory infections
[17,45,46]. The same correlation was shown for other
hormones as Proadrenomedullin [47,48]. This may be ex-
plained by the fact that ADH production in the posterior
pituitary gland is directly positively regulated through
corticotropin-releasing hormone (CRH) and itself stimu-
lates corticotropin secretion in the adrenal pituitary.
ADH thus acts as a stress hormone, similar to cortisol,
and retains fluids in the body during situations of acute
stress. Based on our analysis, we believe that in severe
disease the stress response per se is the dominant stimu-
lus for the upregulation of ADH, and overrules the os-
motic stimulation. Still, as evidenced by the positive
correlation between sodium levels and ADH-precursors,
the physiological osmoregulatory stimulus to ADH secre-
tions seems to be intact in this patient population.
Other mechanisms may explain why patients with
Legionnaires’ disease frequently have low sodium levels.
Figure 1 Admission sodium (A) and CT-ProVasopressin (B) levels
in Legionnaires’ disease, and CAP of other (unknown) etiology.
Legend: The lines indicate median values, the boxes indicate upper and
lower quartiles of the data, while the whiskers indicate the minimum and
maximum values. * p < 0.01.
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First, studies have shown direct effects of cytokines on
the kidney leading to renal salt loss [49-51]. Haines et al.
postulated a direct nephrotoxic effect of Legionella sp., in
some cases leading to acute tubular necrosis or intersti-
tial nephritis with salt loss [9]. Also, other natriuretic
hormones may be important in this regard. Different
studies have reported increased levels of atrial natriuretic
peptide (ANP), as well as B-type-natriuretic peptide
(BNP) in patients with pneumonia [52-54]. These hor-
mones may contribute to low sodium levels via increased
natriuresis.
The strengths of our study are the systematic assessment
of sodium and CT-ProVasopressin in a large prospective
study of patients with CAP of different etiologies. Yet, this
study also has limitations. First, we did not measure
Figure 2 Correlation of sodium (A) and CT-ProVasopressin (B) levels in patients with CAP of other/unknown etiology and
Legionnaires’ disease.
Table 2 Association of low sodium level (<130 mmol/L)
and Legionnaires’ disease in univariate and multivariate
logistic regression models
Parameter OR (95% CI) p
Univariate model 9.01 (95% CI 4.05, 20.01) <0.001
Legionella (vs other etiology)
Multivariate model* 7.74 (95% CI 3.26, 18.38) <0.001
Legionella (vs other etiology)
Multivariate model including
CT-ProVasopressin†
7.53 (95% CI 3.17, 19.90) <0.001
Legionella (vs other etiology)
*adjusted for of age, gender, severity as assessed with the CURB65 score and
markers of inflammation (CRP), infection (PCT) and renal function (creatinine).
†adjusted for above parameters as a well as CT-ProVasopressin.
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mature ADH directly. However, clinical evidence sug-
gests that CT-ProVasopressin is a good surrogate for
ADH, and may thus be used instead in clinical routine
[55]. Still, the ratio of CT-ProVasopressin to ADH plasma
concentrations may be increased in patients with sepsis,
suggesting that CT-ProVasopressin may somewhat over-
estimate ADH plasma concentrations in patients with
severe medical conditions [18]. Second, we were not
able to assess sodium and osmolarity measurements in
urine limiting our model to the measurement of CT-
ProVasopressin and correlating blood sodium levels.
Our observations were rather on the population level and
not on a patient level [16,37,56]. Last, there may have
been unmeasured confounders in our study population
such as the use of diuretics and aldosterone antagonist,
which were not recorded.
Conclusions
In conclusion, we confirm a high prevalence of hypo-
natremia in Legionnaires’ disease compared to other
CAP etiologies. But our report does not lend support
to the hypothesis of elevated ADH levels causing hypo-
natremia in Legionnaires’ disease nor in CAP of other
etiology. Rather, ADH was upregulated in response to
the stress of severe infection, which seemed to have
overruled the osmoregulatory stimulus. Other ADH-
independent mechanisms are more likely to cause salt
loss during Legionnaires’ disease, such as direct renal
effects of cytokines or toxins, as well as natriuretic
hormones. As a consequence, free water restriction
should not be pursued in this patient population, but
rather replacement of salt losses by hydration and salt
repletion.
Figure 3 Plasma sodium (A) and CT-ProVasopressin (B) according to CAP severity assessed with the CURB65 score in patients with
Legionnaires’ disease (dark grey) and patients with other CAP aetiology (light grey).
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